<DOC>
	<DOCNO>NCT02824354</DOCNO>
	<brief_summary>Nalmefene first drug obtain Marketing Authorisation France reduction alcohol consumption . It appear significantly effective group heavy drinker , mean alcohol consumption study conduct cirrhotic patient great 120 g/day . No data available concern nalmefene alcohol-dependent patient alcoholic cirrhosis . However , nalmefene could represent attractive alternative reduce heavy drinking patient alcoholic cirrhosis , potential improvement liver function . No comparator available nalmefene , molecule require abstinence prior start treatment .</brief_summary>
	<brief_title>Nalmefene Patients With Alcoholic Compensated Cirrhosis Treatment Alcohol Dependence .</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Alcoholism</mesh_term>
	<mesh_term>Ethanol</mesh_term>
	<mesh_term>Nalmefene</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>patient sign date informed consent form , blood alcohol concentration &lt; 0.02 % screen visit , alcoholdependent patient accord DSMIVTR criterion , patient compensate cirrhosis ( cirrhosis demonstrate clinical laboratory and/or morphological examination and/or noninvasive test and/or liver biopsy ) , Child A B , patient least high drinking risk level ( moderate risk level define consumption ≥ 60 g alcohol/day men ≥ 40 g alcohol/day woman ) , male female , age 18 year , exclude protect major , patient stable address telephone number , name address family member contact event loss contact patient , woman childbearing potential : must accept become pregnant study , must use effective method contraception ( adequate contraception define oral , systemic contraception , intrauterine device , diaphragm combination spermicide , condom male partner combination spermicide ) , must last natural menstruation ≥ 24 month screen visit , must surgically sterilize screen visit , must undergo hysterectomy screen visit , must sexual activity male partner patient cover French national health insurance . cirrhosis Child Pugh C ( decompensated cirrhosis ) cirrhosis complicate hepatocellular carcinoma type I II hepatorenal syndrome poorly control portal hypertension , severe acute alcoholic hepatitis , respond corticosteroid 7th day define Lille model &gt; 0.56 ( www.lillemodel.com/score.asp ) hepatic encephalopathy 6 month precede screen visit , patient few 6 heavy drinking day 4 week precede screen visit ( heavy drinking day define alcohol consumption ≥ 60 g/day men , ≥ 40 g/day woman ) , patient least 14 consecutive day abstinence 4 week precede screen visit , patient CIWAAr score ( Revised Clinical Institute Withdrawal Assessment Alcohol ) ≥ 10 , patient : disorder alcohol nicotine dependence , evaluate MINI ( MiniInternational Neuropsychiatric Interview ) antisocial personality disorder evaluate MINI questionnaire , disorder treatment must take priority treatment alcohol dependence , likely interfere study treatment compromise adherence treatment , cannabis use constitute exclusion criterion except meet criterion cannabis dependence patient suicide risk evaluate use suicidal tendency module MINI ( patient answer `` Yes '' one question C2 , C3 , C4 , C5 C6 questionnaire ) , patient history delirium tremens alcohol withdrawal seizure , ongoing use addictive substance cannabis , nicotine benzodiazepine , presence disorder comprehension , mental retardation encephalopathy , presence clinically significant unstable disease ( e.g . : renal failure , cardiovascular , pulmonary , gastrointestinal , gastrointestinal , endocrine , neurological , infectious , neoplastic disease metabolic disorder , clinically significant ECG abnormality , history serious drug allergy hypersensitivity nalmefene , ongoing recent treatment ( 3 month precede screen visit ) disulfiram , acamprosate , topiramate , naltrexone , carbimide , opioid antagonist , ongoing recent treatment ( 1 week precede screen visit ) opioid agonists partial agonist , ongoing recent treatment ( 8 week precede screen visit ) antipsychotic antidepressant , patient take take concomitant medication ( see supplementary table ) , patient another disease take medication , , investigator 's opinion , could interfere evaluation safety , tolerability efficacy , treatment investigational medicinal product 30 day precede screen visit , ongoing recent participation ( 4 week precede screen visit ) drinking disorder treatment support programme , include Alcoholics Anonymous , disintoxication treatment treatment alcohol withdrawal symptom , pregnancy breastfeeding , patient , investigator 's opinion , little chance comply protocol unsuitable study reason , patient already participate clinical trial nalmefene .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>